ARWR241220C23000
- 0.90
- +0.50+125.00%
Arrowhead Pharmaceuticals Newsroom
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Arrowhead Pharmaceuticals' Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)
Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $27
Arrowhead Pharma Analyst Ratings
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Buy Rating Justified by Arrowhead Pharmaceuticals' Advancements in CNS-Targeted RNAi Therapeutics
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $28 to $62
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29
Maintaining Hold on Arrowhead Pharmaceuticals Amid Promising CNS Portfolio Developments
Arrowhead Pharma Analyst Ratings
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $42
Arrowhead Pharmaceuticals (ARWR) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60